Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) CEO Steven Gourlay is with Proactive’s Jonathan Jackson live from the ASX Small and Mid Cap Conference in March 2024. In a nutshell, the biotechnology company is developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. According to Actinogen, there is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long term cognitive health.
Sewell says the company is developing its lead compound, Xanamem®, as a new therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome and other neurological diseases where reducing cortisol inside brain cells could have a positive impact.